

**Clinical trial results:****A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients with Risk of Early Disease Progression****Summary**

EudraCT number	2013-003211-22
Trial protocol	DE
Global end of trial date	11 July 2022

Results information

Result version number	v1 (current)
This version publication date	24 August 2023
First version publication date	24 August 2023

Trial information**Trial identification**

Sponsor protocol code	CLL12
-----------------------	-------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02863718
WHO universal trial number (UTN)	-
Other trial identifiers	Board Approval Number: 13-396

Notes:

Sponsors

Sponsor organisation name	University of Cologne
Sponsor organisation address	Albertus-Magnus-Platz 1, Cologne, Germany, 50923
Public contact	Marie Kronmüller, University Hospital Cologne, Department I of Internal Medicine, Kerpener Strasse 62, 50937 Cologne, 0049 22147888220, cli-studie@uk-kolen.de
Scientific contact	Dr. med. Petra Langerbeins, University Hospital Cologne, Department I of Internal Medicine, Kerpener Strasse 62, 50937 Cologne, 0049 22147888220, cli-studie@uk-kolen.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 December 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	11 July 2022
Global end of trial reached?	Yes
Global end of trial date	11 July 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study is to demonstrate superiority of ibrutinib over placebo in prolonging EFS for subjects with treatment-naïve CLL stage A and intermediate or (very) high risk of disease progression. All subjects with intermediate, (very) high risk randomized to the treatment arm will be treated up to active progressive disease with treatment indication according to iwCLL-Guidelines with the objective to demonstrate prolongation of EFS for the ibrutinib arm. EFS is defined as the time between randomization until active progressive disease with treatment indication according to the iwCLL-Guidelines, initiation of subsequent treatment for CLL, or death.

Protection of trial subjects:

Safety measures to prevent or to manage known risks associated with CLL, such as infections or cytopenia or known adverse reactions related to ibrutinib, such as bleeding events, cardiac arrhythmias and cardiac failure, hypertension and diarrhea have been included in the protocol. In chapter 2.4 of the protocol the most frequent risks were described, including recommendations how to prevent and manage these potential adverse events. The protocol includes sections (section 8.6.) regarding permitted and prohibited medication respectively, known interactions and precautions with concomitant medication, especially with CYP3A4 inhibitors or inducers. The protocol provides clear guidance for dose modifications and treatment discontinuation.

Background therapy:

Asymptomatic patients with early-stage disease (Rai 0, Binet A), should be monitored without therapy unless they have evidence of rapid disease progression. So far, studies on early-stage disease were unable to show a benefit of early therapeutic interventions.

Evidence for comparator:

To date no proven effective intervention for Binet A patients exists and watchful waiting should remain state of the art, especially, because published data do not support the concern, that a "delayed" (start only, when disease progresses to a treatment requiring disease according to the iwCLL guidelines) treatment would lead to a disadvantage of patients in early stage disease. Hence, the use of placebo as the comparator arm was considered justified.

Actual start date of recruitment	05 May 2014
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	8 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 515
Worldwide total number of subjects	515
EEA total number of subjects	515

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	313
From 65 to 84 years	201
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

From 5 May 2014 to 14 February 2019, 648 patients consented to participate in the study and were screened for eligibility, of which 133 patients were excluded. A total of 515 patients were enrolled, 152 low-risk patients were allocated to the observational cohort, 182 and 181 patients were randomly assigned to receive ibrutinib and placebo.

Pre-assignment

Screening details:

From 133 Screening failures, 73 did not meet eligibility criteria, 50 withdrew consent, 4 did not complete risk stratification and 6 were screening failures due to administrative reasons.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst

Blinding implementation details:

The randomization procedure was accomplished by a validated interactive web response system (IWRS). Patients were stratified by TP53 mutation status and risk group. Patients, site staff, and the sponsor's clinical and medical representatives were unaware of treatment group assignments. Ibrutinib and placebo capsules were identical in appearance. The blinding was not broken throughout the study unless it was absolutely considered essential.

Arms

Are arms mutually exclusive?	Yes
Arm title	Ibrutinib

Arm description:

Patients were instructed to take 3 capsules (for a dose of 420 mg Ibrutinib) once daily. One cycle was defined as 28 calendar days. Dose modifications were allowed for the management of adverse events (AEs). Study drug could be paused for a maximum of 28 consecutive days.

Arm type	Experimental
Investigational medicinal product name	Ibrutinib
Investigational medicinal product code	SUB120863
Other name	EU/1/14/945/001
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Ibrutinib 420mg will be administered daily up to active progressive disease with treatment indication according to iwCLL-Guidelines. A cycle is defined as 28 calendar days. Ibrutinib was administered until active progressive disease with treatment indication according to iwCLL guidelines or unacceptable toxicity was assessed. If a subject showed signs of progression, the subject was allowed to continue study drug treatment until active progressive disease with treatment indication according to the iwCLL Guidelines was observed.

Arm title	Placebo
------------------	---------

Arm description:

Subjects received placebo. A cycle is defined as 28 calendar days. Placebo was continued until active progressive disease with treatment indication according to iwCLL guidelines or unacceptable toxicity was observed. If a subject showed signs of progression, the subject was allowed to continue study drug treatment until active progressive disease with treatment indication according to the iwCLL guidelines was assessed.

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
Investigational medicinal product code	PL1
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use
Dosage and administration details:	
Placebo to match capsules were also provided as a gray, size 0 hard gelatin capsule for oral administration. Subjects were instructed to take 3 capsules (for a dose of 420 mg), orally once daily.	
Arm title	Watch and Wait
Arm description:	
Subjects at low risk were not randomized and did not receive treatment but were only followed by watch & wait.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 1	Ibrutinib	Placebo	Watch and Wait
Started	182	181	152
Completed	64	33	152
Not completed	118	148	0
Any study treatment received	15	10	-
Progressive disease requiring treatment	4	66	-
Consent withdrawn by subject	1	4	-
Adverse event, non-fatal	75	40	-
New CLL treatment without progressive disease	1	-	-
Death	1	1	-
Non-compliance	12	21	-
Other reason	9	6	-

Baseline characteristics

Reporting groups

Reporting group title	Ibrutinib
-----------------------	-----------

Reporting group description:

Patients were instructed to take 3 capsules (for a dose of 420 mg Ibrutinib) once daily. One cycle was defined as 28 calendar days. Dose modifications were allowed for the management of adverse events (AEs). Study drug could be paused for a maximum of 28 consecutive days.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received placebo. A cycle is defined as 28 calendar days. Placebo was continued until active progressive disease with treatment indication according to iwCLL guidelines or unacceptable toxicity was observed. If a subject showed signs of progression, the subject was allowed to continue study drug treatment until active progressive disease with treatment indication according to the iwCLL guidelines was assessed.

Reporting group title	Watch and Wait
-----------------------	----------------

Reporting group description:

Subjects at low risk were not randomized and did not receive treatment but were only followed by watch & wait.

Reporting group values	Ibrutinib	Placebo	Watch and Wait
Number of subjects	182	181	152
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	100	93	120
From 65-84 years	81	88	32
85 years and over	1	0	0
Age continuous			
Units: years			
median	64	64	57
inter-quartile range (Q1-Q3)	55 to 70	55 to 70	52 to 63
Gender categorical			
Units: Subjects			
Female	45	54	85
Male	137	127	67
GCLLSG Prognostic Index Risk Group			
Units: Subjects			
low	0	0	152
intermediate	137	136	0
high	40	42	0
very high	5	3	0
missing	0	0	0
Binet Stage			

The Binet staging system is one of the two staging systems currently adopted in assessment of chronic lymphocytic leukemia (CLL). It classifies CLL according to the number of involved regions (spleen, liver and the axillary, cervical and inguinal lymph nodes), as well as the presence of anemia or thrombocytopenia.

Units: Subjects			
Binet A	181	181	152
Binet B	1	0	0
Binet C	0	0	0

Cytogenetic subgroup by hierarchical order

Döhner et al first published a hierarchical model including five categories for chromosomal abnormalities (deletion 17p, deletion 11q, trisomy 12, no abnormalities according to the Döhner's model, deletion 13q) with prognostic value in CLL, with the shortest survival estimates observed in patients with del(17p), followed by those with del(11q) in the absence of del(17p).

Units: Subjects			
Deletion 17p	6	7	0
Deletion 11q	21	19	0
Trisomy 12	24	28	4
No abnormalities according to Doehner's model	36	30	27
Deletion 13q	95	97	121

CIRS Score

The Cumulative Illness Rating Scale (CIRS) is a comprehensive tool to evaluate comorbidities, which has been validated in multiple medical settings and is increasingly used in CLL. 14 organ categories can be scored according to the severeness of potential comorbidities with a score between 0 and 4.

Units: Score points			
median	2	3	2
inter-quartile range (Q1-Q3)	1.0 to 4.3	1.0 to 4.0	0.0 to 3.0

Reporting group values	Total		
Number of subjects	515		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	313		
From 65-84 years	201		
85 years and over	1		
Age continuous			
Units: years			
median			
inter-quartile range (Q1-Q3)	-		
Gender categorical			
Units: Subjects			
Female	184		
Male	331		
GCLLSG Prognostic Index Risk Group			
Units: Subjects			
low	152		

intermediate	273		
high	82		
very high	8		
missing	0		
Binet Stage			
The Binet staging system is one of the two staging systems currently adopted in assessment of chronic lymphocytic leukemia (CLL). It classifies CLL according to the number of involved regions (spleen, liver and the axillary, cervical and inguinal lymph nodes), as well as the presence of anemia or thrombocytopenia.			
Units: Subjects			
Binet A	514		
Binet B	1		
Binet C	0		
Cytogenetic subgroup by hierarchical order			
Döhner et al first published a hierarchical model including five categories for chromosomal abnormalities (deletion 17p, deletion 11q, trisomy 12, no abnormalities according to the Döhner's model, deletion 13q) with prognostic value in CLL, with the shortest survival estimates observed in patients with del(17p), followed by those with del(11q) in the absence of del(17p).			
Units: Subjects			
Deletion 17p	13		
Deletion 11q	40		
Trisomy 12	56		
No abnormalities according to Doehner's model	93		
Deletion 13q	313		
CIRS Score			
The Cumulative Illness Rating Scale (CIRS) is a comprehensive tool to evaluate comorbidities, which has been validated in multiple medical settings and is increasingly used in CLL. 14 organ categories can be scored according to the severeness of potential comorbidities with a score between 0 and 4.			
Units: Score points			
median			
inter-quartile range (Q1-Q3)	-		

End points

End points reporting groups

Reporting group title	Ibrutinib
Reporting group description: Patients were instructed to take 3 capsules (for a dose of 420 mg Ibrutinib) once daily. One cycle was defined as 28 calendar days. Dose modifications were allowed for the management of adverse events (AEs). Study drug could be paused for a maximum of 28 consecutive days.	
Reporting group title	Placebo
Reporting group description: Subjects received placebo. A cycle is defined as 28 calendar days. Placebo was continued until active progressive disease with treatment indication according to iwCLL guidelines or unacceptable toxicity was observed. If a subject showed signs of progression, the subject was allowed to continue study drug treatment until active progressive disease with treatment indication according to the iwCLL guidelines was assessed.	
Reporting group title	Watch and Wait
Reporting group description: Subjects at low risk were not randomized and did not receive treatment but were only followed by watch & wait.	

Primary: Event-free Survival

End point title	Event-free Survival ^[1]
End point description: The analysis of the primary efficacy parameter EFS will be performed on the population of all patients with intermediate, high or very high risk being randomized to receive ibrutinib or placebo using a two-sided stratified log-rank test with risk group as stratification factor (intermediate risk / high risk / very high risk) (at 0.05 significance level; not adjusted). In addition Kaplan-Meier survival methodology will be used to calculate the median EFS and estimated EFS rates for one, two and three years etc. after randomization. The corresponding hazard ratio and 95% confidence interval will be determined using a stratified (by risk group) Cox proportional hazard regression model.	
End point type	Primary
End point timeframe: The primary efficacy parameter is event-free survival (EFS) defined as the time of randomization until symptomatic disease progression with treatment indication, initiation of subsequent treatment for CLL or death by any cause, whichever occurs first.	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The primary objective of the study is to demonstrate superiority of ibrutinib over placebo in prolonging event-free survival in treatment naïve Binet stage A CLL patients with intermediate to (very) high risk of disease progression. Therefore this analysis was based on randomized patients of the two treatment arms with ibrutinib or placebo.

End point values	Ibrutinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	182 ^[2]	181		
Units: Percentage				
number (not applicable)				
Median EFS (months)	0	51.6		
1-year survival	96.4	88.9		
2-year survival	90.9	74.5		

3-year survival	87.7	61.2		
4-year survival	84.1	52.2		
5-year survival	78.2	48.0		

Notes:

[2] - Median EFS was not reached in this subgroup.

Statistical analyses

Statistical analysis title	Stratified log-rank test regarding EFS
Statistical analysis description:	
Treatment comparison for the primary efficacy parameter EFS will be performed using a two-sided stratified log-rank test using the GCLLSG Prognostic Index Risk Group as stratification factor (at 0.05 significance level; not adjusted).	
Comparison groups	Ibrutinib v Placebo
Number of subjects included in analysis	363
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	log-rank test

Statistical analysis title	Cox regression regarding EFS
Statistical analysis description:	
Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 95% confidence interval estimated through a stratified (by the GCLLSG Prognostic Index Risk Group) Cox proportional hazard regression model. If the null hypothesis is rejected and the observed HR is favorable for the ibrutinib arm, then it is concluded that early treatment with ibrutinib significantly lowers the risk of EFS events in Binet stage A CLL patients with increased risk of disease progression.	
Comparison groups	Ibrutinib v Placebo
Number of subjects included in analysis	363
Analysis specification	Pre-specified
Analysis type	superiority ^[3]
Parameter estimate	Cox proportional hazard
Point estimate	0.276
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.188
upper limit	0.407

Notes:

[3] - In Cox-regression the Placebo-group was used as reference category (Ibrutinib vs. Placebo).

Secondary: Overall survival

End point title	Overall survival ^[4]
End point description:	
The analysis of the secondary efficacy endpoint OS will be performed on the population of all patients with intermediate, high or very high risk being randomized to receive ibrutinib or placebo using a two-sided stratified log-rank test with risk group as stratification factor (intermediate risk / high risk / very high risk).	
In addition Kaplan-Meier survival methodology will be used to calculate the median OS and estimated OS rates for one, two and three years etc. after randomization. The corresponding hazard ratio and 95% confidence interval will be determined using a stratified (by risk group) Cox proportional hazard regression model.	

End point type	Secondary
----------------	-----------

End point timeframe:

Overall survival (OS) will be calculated from the date of randomization to the date of death due to any cause. Subjects who have not yet died at the time of analysis will be censored at the date of last observation they were assessed to be alive.

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The secondary objective of the study is to demonstrate superiority of ibrutinib over placebo in treatment naïve Binet stage A CLL patients with intermediate to (very) high risk of disease progression in prolonging overall survival. Therefore this analysis was based on randomized patients of the two treatment arms with ibrutinib or placebo.

End point values	Ibrutinib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	182 ^[5]	181 ^[6]		
Units: Percentage				
number (not applicable)				
Median OS	0	0		
1-year survival	98.8	100.0		
2-year survival	97.6	100.0		
3-year survival	97.0	98.8		
4-year survival	94.1	96.0		
5-year survival	93.3	93.6		

Notes:

[5] - Median OS was not reached in this subgroup.

[6] - Median OS was not reached in this subgroup.

Statistical analyses

Statistical analysis title	Stratified log-rank test regarding OS
-----------------------------------	---------------------------------------

Statistical analysis description:

Treatment comparison for the secondary efficacy parameter OS will be performed using a two-sided stratified log-rank test using the GCLLSG Prognostic Index Risk Group as stratification factor.

Comparison groups	Placebo v Ibrutinib
Number of subjects included in analysis	363
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.562
Method	log-rank test

Statistical analysis title	Cox regression regarding OS
-----------------------------------	-----------------------------

Statistical analysis description:

Estimates of the treatment effect will be expressed by the hazard ratio (HR) including the 95% confidence interval estimated through a stratified (by the GCLLSG Prognostic Index Risk Group) Cox proportional hazard regression model.

Comparison groups	Ibrutinib v Placebo
-------------------	---------------------

Number of subjects included in analysis	363
Analysis specification	Pre-specified
Analysis type	superiority ^[7]
Parameter estimate	Cox proportional hazard
Point estimate	0.791
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.358
upper limit	1.748

Notes:

[7] - In Cox-regression the Placebo-group was used as reference category (Ibrutinib vs. Placebo).

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Timeframe for AE

Adverse event reporting additional description:

AE additional description

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Reporting group title	Ibrutinib
-----------------------	-----------

Reporting group description: -

Serious adverse events	Placebo	Ibrutinib	
Total subjects affected by serious adverse events			
subjects affected / exposed	101 / 168 (60.12%)	102 / 170 (60.00%)	
number of deaths (all causes)	14	11	
number of deaths resulting from adverse events	13	10	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adrenal adenoma	Additional description: Adrenal adenoma		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer	Additional description: Breast cancer		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of bladder	Additional description: Benign neoplasm of bladder		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma	Additional description: Basal cell carcinoma		

subjects affected / exposed	12 / 168 (7.14%)	4 / 170 (2.35%)	
occurrences causally related to treatment / all	2 / 18	3 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear cell renal cell carcinoma	Additional description: Clear cell renal cell carcinoma		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon adenoma	Additional description: Colon adenoma		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer	Additional description: Endometrial cancer		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal stromal tumour	Additional description: Gastrointestinal stromal tumour		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraductal papilloma of breast	Additional description: Intraductal papilloma of breast		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma	Additional description: Lung adenocarcinoma		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lung neoplasm malignant	Additional description: Lung neoplasm malignant		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Malignant melanoma	Additional description: Malignant melanoma		

subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningioma			
Additional description: Meningioma			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelodysplastic syndrome			
Additional description: Myelodysplastic syndrome			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liposarcoma			
Additional description: Liposarcoma			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma of the skin			
Additional description: Neuroendocrine carcinoma of the skin			
subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nodular melanoma			
Additional description: Nodular melanoma			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer			
Additional description: Non-small cell lung cancer			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian adenoma			
Additional description: Ovarian adenoma			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cancer			
Additional description: Ovarian cancer			

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Rectal adenocarcinoma	Additional description: Rectal adenocarcinoma		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer	Additional description: Prostate cancer		
subjects affected / exposed	5 / 168 (2.98%)	4 / 170 (2.35%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer metastatic	Additional description: Renal cancer metastatic		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Small cell lung cancer	Additional description: Small cell lung cancer		
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Richter's syndrome	Additional description: Richter's syndrome		
subjects affected / exposed	5 / 168 (2.98%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 3	0 / 0	
Thyroid cancer	Additional description: Thyroid cancer		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma	Additional description: Squamous cell carcinoma		
subjects affected / exposed	4 / 168 (2.38%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	1 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin	Additional description: Squamous cell carcinoma of skin		

subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uveal melanoma			
Additional description: Uveal melanoma			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Circulatory collapse			
Additional description: Circulatory collapse			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
Additional description: Hypertension			
subjects affected / exposed	1 / 168 (0.60%)	3 / 170 (1.76%)	
occurrences causally related to treatment / all	1 / 1	2 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
Additional description: Haematoma			
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
Additional description: Hypertensive crisis			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jugular vein distension			
Additional description: Jugular vein distension			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
Additional description: Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
Additional description: Subdural haemorrhage			

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb	Additional description: Venous thrombosis limb		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures	Additional description: Cardiac pacemaker replacement		
Cardiac pacemaker replacement	Additional description: Cardiac pacemaker replacement		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac resynchronisation therapy	Additional description: Cardiac resynchronisation therapy		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary arterial stent insertion	Additional description: Coronary arterial stent insertion		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device removal	Additional description: Medical device removal		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroprosthesis implantation	Additional description: Neuroprosthesis implantation		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatectomy	Additional description: Prostatectomy		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			

Chest pain	Additional description: Chest pain		
	subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)
	occurrences causally related to treatment / all	0 / 0	0 / 2
	deaths causally related to treatment / all	0 / 0	0 / 0
Death	Additional description: Death		
	subjects affected / exposed	4 / 168 (2.38%)	2 / 170 (1.18%)
	occurrences causally related to treatment / all	0 / 4	0 / 2
	deaths causally related to treatment / all	0 / 4	0 / 2
Hernia	Additional description: Hernia		
	subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
	occurrences causally related to treatment / all	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0
General physical health deterioration	Additional description: General physical health deterioration		
	subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)
	occurrences causally related to treatment / all	0 / 2	0 / 0
	deaths causally related to treatment / all	0 / 1	0 / 0
Necrosis	Additional description: Necrosis		
	subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
	occurrences causally related to treatment / all	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0
Pyrexia	Additional description: Pyrexia		
	subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
	occurrences causally related to treatment / all	0 / 1	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0
Sudden cardiac death	Additional description: Sudden cardiac death		
	subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
	occurrences causally related to treatment / all	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 1
Ulcer	Additional description: Ulcer		
	subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
	occurrences causally related to treatment / all	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0
Immune system disorders			

Drug hypersensitivity	Additional description: Drug hypersensitivity		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders	Additional description: Benign prostatic hyperplasia		
Benign prostatic hyperplasia	Additional description: Benign prostatic hyperplasia		
subjects affected / exposed	2 / 168 (1.19%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic floor muscle weakness	Additional description: Pelvic floor muscle weakness		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal prolapse	Additional description: Vaginal prolapse		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders	Additional description: Asthma-chronic obstructive pulmonary disease overlap syndrome		
Asthma-chronic obstructive pulmonary disease overlap syndrome	Additional description: Asthma-chronic obstructive pulmonary disease overlap syndrome		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma	Additional description: Asthma		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea	Additional description: Dyspnoea		
subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease	Additional description: Interstitial lung disease		

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal septum deviation	Additional description: Nasal septum deviation		
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion	Additional description: Pleural effusion		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism	Additional description: Pulmonary embolism		
subjects affected / exposed	3 / 168 (1.79%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sleep apnoea syndrome	Additional description: Sleep apnoea syndrome		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders	Additional description: Delusion of parasitosis		
Delusion of parasitosis	Additional description: Delusion of parasitosis		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression	Additional description: Depression		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations	Additional description: Catheterisation cardiac		
Catheterisation cardiac	Additional description: Catheterisation cardiac		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical observation	Additional description: Medical observation		

subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Ankle fracture Additional description: Ankle fracture			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fractured sacrum Additional description: Fractured sacrum			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture Additional description: Foot fracture			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture Additional description: Femur fracture			
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture Additional description: Femoral neck fracture			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial bones fracture Additional description: Facial bones fracture			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture Additional description: Humerus fracture			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infusion related reaction Additional description: Infusion related reaction			

subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
Additional description: Joint dislocation			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb fracture			
Additional description: Limb fracture			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
Additional description: Lumbar vertebral fracture			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
Additional description: Meniscus injury			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple fractures			
Additional description: Multiple fractures			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural nausea			
Additional description: Procedural nausea			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
Additional description: Radius fracture			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
Additional description: Rib fracture			

subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident	Additional description: Road traffic accident		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin laceration	Additional description: Skin laceration		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture	Additional description: Spinal fracture		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic rupture	Additional description: Splenic rupture		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage	Additional description: Subarachnoid haemorrhage		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma	Additional description: Subdural haematoma		
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	1 / 1	
Tendon rupture	Additional description: Tendon rupture		
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents	Additional description: Toxicity to various agents		

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Tibia fracture	Additional description: Tibia fracture		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Vaccination complication	Additional description: Vaccination complication		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cardiac disorders			
Atrial fibrillation	Additional description: Atrial fibrillation		
subjects affected / exposed	3 / 168 (1.79%)	11 / 170 (6.47%)	
occurrences causally related to treatment / all	2 / 4	9 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	

Arteriosclerosis coronary artery	Additional description: Arteriosclerosis coronary artery		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Acute myocardial infarction	Additional description: Acute myocardial infarction		
subjects affected / exposed	5 / 168 (2.98%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	1 / 5	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Atrial flutter	Additional description: Atrial flutter		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cardiac arrest	Additional description: Cardiac arrest		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	

Cardiac aneurysm	Additional description: Cardiac aneurysm		

subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorder	Additional description: Cardiac disorder		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive	Additional description: Cardiac failure congestive		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic coronary syndrome	Additional description: Chronic coronary syndrome		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure	Additional description: Cardiac failure		
subjects affected / exposed	3 / 168 (1.79%)	3 / 170 (1.76%)	
occurrences causally related to treatment / all	0 / 4	1 / 3	
deaths causally related to treatment / all	0 / 1	1 / 1	
Congestive cardiomyopathy	Additional description: Congestive cardiomyopathy		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease	Additional description: Coronary artery disease		
subjects affected / exposed	6 / 168 (3.57%)	6 / 170 (3.53%)	
occurrences causally related to treatment / all	0 / 6	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis	Additional description: Coronary artery stenosis		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence	Additional description: Mitral valve incompetence		

subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
Additional description: Sinus tachycardia			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia paroxysmal			
Additional description: Tachycardia paroxysmal			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tricuspid valve incompetence			
Additional description: Tricuspid valve incompetence			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			
Additional description: Ventricular tachycardia			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Basilar artery thrombosis			
Additional description: Basilar artery thrombosis			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal ganglia infarction			
Additional description: Basal ganglia infarction			
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal ganglia haemorrhage			
Additional description: Basal ganglia haemorrhage			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar infarction			
Additional description: Cerebellar infarction			

subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
Additional description: Cerebral haemorrhage			
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral ischaemia			
Additional description: Cerebral ischaemia			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
Additional description: Cerebrovascular accident			
subjects affected / exposed	3 / 168 (1.79%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicobrachial syndrome			
Additional description: Cervicobrachial syndrome			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia			
Additional description: Dementia			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
Additional description: Dizziness			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness postural			
Additional description: Dizziness postural			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
Additional description: Epilepsy			

subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolitic stroke			
Additional description: Embolitic stroke			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
Additional description: Lumbar radiculopathy			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurodegenerative disorder			
Additional description: Neurodegenerative disorder			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral sensory neuropathy			
Additional description: Peripheral sensory neuropathy			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Posterior reversible encephalopathy syndrome			
Additional description: Posterior reversible encephalopathy syndrome			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculopathy			
Additional description: Radiculopathy			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
Additional description: Sciatica			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
Additional description: Seizure			

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage	Additional description: Subarachnoid haemorrhage		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope	Additional description: Syncope		
subjects affected / exposed	1 / 168 (0.60%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombotic stroke	Additional description: Thrombotic stroke		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack	Additional description: Transient ischaemic attack		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Febrile neutropenia	Additional description: Febrile neutropenia		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemolytic anaemia	Additional description: Haemolytic anaemia		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemolysis	Additional description: Haemolysis		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis	Additional description: Leukocytosis		

subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
Additional description: Neutropenia			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic haematoma			
Additional description: Splenic haematoma			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Meniere's disease			
Additional description: Meniere's disease			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
Additional description: Vertigo			
subjects affected / exposed	2 / 168 (1.19%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Glaucoma			
Additional description: Glaucoma			
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion			
Additional description: Retinal artery occlusion			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal degeneration			
Additional description: Retinal degeneration			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal haemorrhage			
Additional description: Retinal haemorrhage			

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Additional description: Abdominal pain			
Abdominal pain			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Additional description: Colitis ischaemic			
Colitis ischaemic			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Additional description: Constipation			
Constipation			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Additional description: Gastrointestinal inflammation			
Gastrointestinal inflammation			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Additional description: Hiatus hernia			
Hiatus hernia			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Additional description: Inguinal hernia			
Inguinal hernia			
subjects affected / exposed	2 / 168 (1.19%)	3 / 170 (1.76%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Additional description: Large intestinal stenosis			
Large intestinal stenosis			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Additional description: Large intestine perforation			
Large intestine perforation			

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis	Additional description: Pancreatitis		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia	Additional description: Umbilical hernia		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders	Additional description: Bile duct stone		
Bile duct stone	Additional description: Bile duct stone		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute	Additional description: Cholecystitis acute		
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis	Additional description: Cholestasis		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatotoxicity	Additional description: Hepatotoxicity		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure	Additional description: Hepatic failure		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			

Rash	Additional description: Rash		
	subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
	occurrences causally related to treatment / all	0 / 1	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0
Skin ulcer	Additional description: Skin ulcer		
	subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)
	occurrences causally related to treatment / all	0 / 3	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0
Renal and urinary disorders	Additional description: Acute kidney injury		
	Acute kidney injury		
	subjects affected / exposed	2 / 168 (1.19%)	1 / 170 (0.59%)
	occurrences causally related to treatment / all	0 / 2	1 / 1
Calculus urinary	Additional description: Calculus urinary		
	subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
	occurrences causally related to treatment / all	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0
Nephrolithiasis	Additional description: Nephrolithiasis		
	subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
	occurrences causally related to treatment / all	0 / 0	0 / 2
	deaths causally related to treatment / all	0 / 0	0 / 0
Postrenal failure	Additional description: Postrenal failure		
	subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
	occurrences causally related to treatment / all	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0
Renal infarct	Additional description: Renal infarct		
	subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
	occurrences causally related to treatment / all	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0
Renal colic	Additional description: Renal colic		
	subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
	occurrences causally related to treatment / all	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0
Ureteric stenosis	Additional description: Ureteric stenosis		

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis	Additional description: Ureterolithiasis		
subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis	Additional description: Urethral stenosis		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary incontinence	Additional description: Urinary incontinence		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Goitre	Additional description: Goitre		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid haemorrhage	Additional description: Thyroid haemorrhage		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain	Additional description: Back pain		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis	Additional description: Bursitis		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Intervertebral disc disorder subjects affected / exposed	Additional description: Intervertebral disc disorder	
	1 / 168 (0.60%)	0 / 170 (0.00%)
	0 / 1	0 / 0
occurrences causally related to treatment / all		
deaths causally related to treatment / all	0 / 0	0 / 0
Intervertebral disc protrusion subjects affected / exposed	Additional description: Intervertebral disc protrusion	
	2 / 168 (1.19%)	0 / 170 (0.00%)
	0 / 2	0 / 0
occurrences causally related to treatment / all		
deaths causally related to treatment / all	0 / 0	0 / 0
Mandibular mass subjects affected / exposed	Additional description: Mandibular mass	
	1 / 168 (0.60%)	0 / 170 (0.00%)
	0 / 1	0 / 0
occurrences causally related to treatment / all		
deaths causally related to treatment / all	0 / 0	0 / 0
Musculoskeletal chest pain subjects affected / exposed	Additional description: Musculoskeletal chest pain	
	0 / 168 (0.00%)	1 / 170 (0.59%)
	0 / 0	1 / 1
occurrences causally related to treatment / all		
deaths causally related to treatment / all	0 / 0	0 / 0
Osteoarthritis subjects affected / exposed	Additional description: Osteoarthritis	
	1 / 168 (0.60%)	3 / 170 (1.76%)
	0 / 1	0 / 4
occurrences causally related to treatment / all		
deaths causally related to treatment / all	0 / 0	0 / 0
Osteochondritis subjects affected / exposed	Additional description: Osteochondritis	
	0 / 168 (0.00%)	1 / 170 (0.59%)
	0 / 0	0 / 1
occurrences causally related to treatment / all		
deaths causally related to treatment / all	0 / 0	0 / 0
Periarthritis subjects affected / exposed	Additional description: Periarthritis	
	1 / 168 (0.60%)	0 / 170 (0.00%)
	0 / 1	0 / 0
occurrences causally related to treatment / all		
deaths causally related to treatment / all	0 / 0	0 / 0
Rotator cuff syndrome subjects affected / exposed	Additional description: Rotator cuff syndrome	
	2 / 168 (1.19%)	1 / 170 (0.59%)
	0 / 4	0 / 1
occurrences causally related to treatment / all		
deaths causally related to treatment / all	0 / 0	0 / 0
Spondylolisthesis	Additional description: Spondylolisthesis	

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovial cyst			
Additional description: Synovial cyst			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal stenosis			
Additional description: Spinal stenosis			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis perforated			
Additional description: Appendicitis perforated			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
Additional description: Abscess limb			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess			
Additional description: Abscess			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
Additional description: Bronchitis			
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial prostatitis			
Additional description: Bacterial prostatitis			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbuncle			
Additional description: Carbuncle			

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis infective			
Additional description: Bursitis infective			
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
Additional description: Clostridium difficile colitis			
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
Additional description: Cellulitis			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium colitis			
Additional description: Clostridium colitis			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dacryocystitis			
Additional description: Dacryocystitis			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
Additional description: Device related infection			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
Additional description: Diverticulitis			
subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
Additional description: COVID-19			

subjects affected / exposed	7 / 168 (4.17%)	7 / 170 (4.12%)	
occurrences causally related to treatment / all	0 / 7	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19 pneumonia	Additional description: COVID-19 pneumonia		
subjects affected / exposed	1 / 168 (0.60%)	3 / 170 (1.76%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cystitis	Additional description: Cystitis		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis escherichia	Additional description: Cystitis escherichia		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus infection	Additional description: Cytomegalovirus infection		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis	Additional description: Gastroenteritis		
subjects affected / exposed	3 / 168 (1.79%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile infection	Additional description: Febrile infection		
subjects affected / exposed	4 / 168 (2.38%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis	Additional description: Escherichia sepsis		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Erysipelas	Additional description: Erysipelas		

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epididymitis			
Additional description: Epididymitis			
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolic pneumonia			
Additional description: Embolic pneumonia			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear infection			
Additional description: Ear infection			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster meningoencephalitis			
Additional description: Herpes zoster meningoencephalitis			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
Additional description: Herpes zoster			
subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cyst infection			
Additional description: Hepatic cyst infection			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Helicobacter gastritis			
Additional description: Helicobacter gastritis			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis E			
Additional description: Hepatitis E			

subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infected dermal cyst	Additional description: Infected dermal cyst		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infection	Additional description: Infection		
subjects affected / exposed	2 / 168 (1.19%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Influenza	Additional description: Influenza		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Injection site abscess	Additional description: Injection site abscess		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Intervertebral discitis	Additional description: Intervertebral discitis		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Lower respiratory tract infection	Additional description: Lower respiratory tract infection		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Lymphangitis	Additional description: Lymphangitis		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Mastoiditis	Additional description: Mastoiditis		

subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenic infection			
Additional description: Neutropenic infection			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenic sepsis			
Additional description: Neutropenic sepsis			
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal candidiasis			
Additional description: Oesophageal candidiasis			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ophthalmic herpes zoster			
Additional description: Ophthalmic herpes zoster			
subjects affected / exposed	1 / 168 (0.60%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral herpes			
Additional description: Oral herpes			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			
Additional description: Orchitis			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
Additional description: Osteomyelitis			
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paronychia			
Additional description: Paronychia			

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis infective	Additional description: Pericarditis infective		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia	Additional description: Pneumonia		
subjects affected / exposed	11 / 168 (6.55%)	8 / 170 (4.71%)	
occurrences causally related to treatment / all	3 / 12	7 / 11	
deaths causally related to treatment / all	0 / 0	0 / 1	
Salmonellosis	Additional description: Salmonellosis		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis	Additional description: Sepsis		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis	Additional description: Staphylococcal sepsis		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis	Additional description: Urosepsis		
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis	Additional description: Tonsillitis		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tracheobronchitis viral	Additional description: Tracheobronchitis viral		

subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection	Additional description: Upper respiratory tract infection		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection	Additional description: Urinary tract infection		
subjects affected / exposed	0 / 168 (0.00%)	3 / 170 (1.76%)	
occurrences causally related to treatment / all	0 / 0	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyperphosphataemia	Additional description: Hyperphosphataemia		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia	Additional description: Hyponatraemia		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour lysis syndrome	Additional description: Tumour lysis syndrome		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus	Additional description: Type 2 diabetes mellitus		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Placebo	Ibrutinib	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	164 / 168 (97.62%)	164 / 170 (96.47%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenoma benign	Additional description: Adenoma benign		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences (all)	1	0	
Angiolipoma	Additional description: Angiolipoma		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences (all)	1	1	
Bowen's disease	Additional description: Bowen's disease		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences (all)	1	0	
Cancer fatigue	Additional description: Cancer fatigue		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences (all)	0	1	
Colon adenoma	Additional description: Colon adenoma		
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)	
occurrences (all)	0	1	
Fibroma	Additional description: Fibroma		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences (all)	1	0	
Haemangioma of liver	Additional description: Haemangioma of liver		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences (all)	1	0	
Kidney angiomyolipoma	Additional description: Kidney angiomyolipoma		
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)	
occurrences (all)	1	0	
Lipoma	Additional description: Lipoma		
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)	
occurrences (all)	1	1	
Melanocytic naevus	Additional description: Melanocytic naevus		
subjects affected / exposed	2 / 168 (1.19%)	1 / 170 (0.59%)	
occurrences (all)	2	2	
Seborrhoeic keratosis	Additional description: Seborrhoeic keratosis		

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Skin papilloma	Additional description: Skin papilloma		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Sweat gland tumour	Additional description: Sweat gland tumour		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Vascular disorders			
Aortic aneurysm	Additional description: Aortic aneurysm		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Arteriosclerosis	Additional description: Arteriosclerosis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Circulatory collapse	Additional description: Circulatory collapse		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2	
Flushing	Additional description: Flushing		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	2 / 170 (1.18%) 3	
Haematoma	Additional description: Haematoma		
subjects affected / exposed occurrences (all)	9 / 168 (5.36%) 11	28 / 170 (16.47%) 40	
Hot flush	Additional description: Hot flush		
subjects affected / exposed occurrences (all)	3 / 168 (1.79%) 4	2 / 170 (1.18%) 2	
Hypertension	Additional description: Hypertension		
subjects affected / exposed occurrences (all)	12 / 168 (7.14%) 12	28 / 170 (16.47%) 31	
Hypertensive crisis	Additional description: Hypertensive crisis		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	2 / 170 (1.18%) 3	
Hypotension	Additional description: Hypotension		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	

Musculoskeletal and connective tissue disorders	Additional description: Musculoskeletal and connective tissue disorders	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Orthostatic hypotension	Additional description: Orthostatic hypotension	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Peripheral vascular disorder	Additional description: Peripheral vascular disorder	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	2
Thrombophlebitis	Additional description: Thrombophlebitis	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Thrombosis	Additional description: Thrombosis	
subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)
occurrences (all)	2	0
Varicophlebitis	Additional description: Varicophlebitis	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Varicose vein	Additional description: Varicose vein	
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)
occurrences (all)	0	2
Surgical and medical procedures		
Bunion operation	Additional description: Bunion operation	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Carpal tunnel decompression	Additional description: Carpal tunnel decompression	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Dental implantation	Additional description: Dental implantation	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Dental operation	Additional description: Dental operation	
subjects affected / exposed	2 / 168 (1.19%)	1 / 170 (0.59%)
occurrences (all)	2	1
Dental prosthesis placement	Additional description: Dental prosthesis placement	

subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Foot operation	Additional description: Foot operation		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Hernia repair	Additional description: Hernia repair		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Jaw operation	Additional description: Jaw operation		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Inguinal hernia repair	Additional description: Inguinal hernia repair		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Lipoma excision	Additional description: Lipoma excision		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Renal stone removal	Additional description: Renal stone removal		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Tooth extraction	Additional description: Tooth extraction		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	0 / 170 (0.00%) 0	
General disorders and administration site conditions			
Asthenia	Additional description: Asthenia		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2	
Axillary pain	Additional description: Axillary pain		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	1 / 170 (0.59%) 1	
Chest pain	Additional description: Chest pain		
subjects affected / exposed occurrences (all)	7 / 168 (4.17%) 8	4 / 170 (2.35%) 4	
Chills	Additional description: Chills		

subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	3 / 170 (1.76%) 3	
Discomfort	Additional description: Discomfort		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Fatigue	Additional description: Fatigue		
subjects affected / exposed occurrences (all)	35 / 168 (20.83%) 39	47 / 170 (27.65%) 61	
Extravasation	Additional description: Extravasation		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Gait disturbance	Additional description: Gait disturbance		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
General physical health deterioration	Additional description: General physical health deterioration		
subjects affected / exposed occurrences (all)	5 / 168 (2.98%) 5	0 / 170 (0.00%) 0	
General symptom	Additional description: General symptom		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Ill-defined disorder	Additional description: Ill-defined disorder		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Impaired healing	Additional description: Impaired healing		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	3 / 170 (1.76%) 3	
Inflammation	Additional description: Inflammation		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 4	
Influenza like illness	Additional description: Influenza like illness		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	3 / 170 (1.76%) 4	
Mucosal inflammation	Additional description: Mucosal inflammation		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Malaise	Additional description: Malaise		

subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	5 / 170 (2.94%) 5	
Oedema	Additional description: Oedema		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	4 / 170 (2.35%) 4	
Oedema peripheral	Additional description: Oedema peripheral		
subjects affected / exposed occurrences (all)	3 / 168 (1.79%) 3	12 / 170 (7.06%) 14	
Performance status decreased	Additional description: Performance status decreased		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Pain	Additional description: Pain		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 2	4 / 170 (2.35%) 6	
Peripheral swelling	Additional description: Peripheral swelling		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	5 / 170 (2.94%) 6	
Polyp	Additional description: Polyp		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed occurrences (all)	3 / 168 (1.79%) 3	7 / 170 (4.12%) 8	
Sensation of foreign body	Additional description: Sensation of foreign body		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Swelling	Additional description: Swelling		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Swelling face	Additional description: Swelling face		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Temperature intolerance	Additional description: Temperature intolerance		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Ulcer	Additional description: Ulcer		

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Vaccination site reaction	Additional description: Vaccination site reaction		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Immune system disorders			
Allergy to arthropod bite	Additional description: Allergy to arthropod bite		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Autoimmune disorder	Additional description: Autoimmune disorder		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Hypersensitivity	Additional description: Hypersensitivity		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Immunisation reaction	Additional description: Immunisation reaction		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2	
Seasonal allergy	Additional description: Seasonal allergy		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	3 / 170 (1.76%) 4	
Reproductive system and breast disorders			
Balanoposthitis	Additional description: Balanoposthitis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Benign prostatic hyperplasia	Additional description: Benign prostatic hyperplasia		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	6 / 170 (3.53%) 6	
Breast cyst	Additional description: Breast cyst		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Breast pain	Additional description: Breast pain		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Endometrial hyperplasia	Additional description: Endometrial hyperplasia		

subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Erectile dysfunction	Additional description: Erectile dysfunction		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	3 / 170 (1.76%) 3	
Genital pain	Additional description: Genital pain		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Gynaecomastia	Additional description: Gynaecomastia		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Menopausal symptoms	Additional description: Menopausal symptoms		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Metrorrhagia	Additional description: Metrorrhagia		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Orchitis noninfective	Additional description: Orchitis noninfective		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Postmenopausal haemorrhage	Additional description: Postmenopausal haemorrhage		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Rectocele	Additional description: Rectocele		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Prostatitis	Additional description: Prostatitis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Scrotal pain	Additional description: Scrotal pain		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2	
Testicular pain	Additional description: Testicular pain		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	3 / 170 (1.76%) 3	
Vulvovaginal pain	Additional description: Vulvovaginal pain		

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Uterine polyp	Additional description: Uterine polyp		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			
Allergic cough	Additional description: Allergic cough		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Asthma	Additional description: Asthma		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Bronchitis chronic	Additional description: Bronchitis chronic		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Bronchostenosis	Additional description: Bronchostenosis		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Chronic obstructive pulmonary disease	Additional description: Chronic obstructive pulmonary disease		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Cough	Additional description: Cough		
subjects affected / exposed occurrences (all)	13 / 168 (7.74%) 17	14 / 170 (8.24%) 18	
Emphysema	Additional description: Emphysema		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Dysphonia	Additional description: Dysphonia		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Dyspnoea	Additional description: Dyspnoea		
subjects affected / exposed occurrences (all)	9 / 168 (5.36%) 10	10 / 170 (5.88%) 11	
Dyspnoea exertional	Additional description: Dyspnoea exertional		

subjects affected / exposed occurrences (all)	7 / 168 (4.17%) 7	4 / 170 (2.35%) 5	
Epistaxis	Additional description: Epistaxis		
subjects affected / exposed occurrences (all)	4 / 168 (2.38%) 4	21 / 170 (12.35%) 29	
Haemoptysis	Additional description: Haemoptysis		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 2	1 / 170 (0.59%) 1	
Increased bronchial secretion	Additional description: Increased bronchial secretion		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Laryngeal haemorrhage	Additional description: Laryngeal haemorrhage		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Lung hypoinflation	Additional description: Lung hypoinflation		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Nasal septum deviation	Additional description: Nasal septum deviation		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Oropharyngeal discomfort	Additional description: Oropharyngeal discomfort		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Oropharyngeal pain	Additional description: Oropharyngeal pain		
subjects affected / exposed occurrences (all)	7 / 168 (4.17%) 9	5 / 170 (2.94%) 7	
Pharyngeal oedema	Additional description: Pharyngeal oedema		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Pleural effusion	Additional description: Pleural effusion		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	3 / 170 (1.76%) 3	
Pulmonary pain	Additional description: Pulmonary pain		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Rhinitis allergic	Additional description: Rhinitis allergic		

subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 3	2 / 170 (1.18%) 2	
Rhinorrhoea	Additional description: Rhinorrhoea		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	4 / 170 (2.35%) 4	
Sleep apnoea syndrome	Additional description: Sleep apnoea syndrome		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Throat clearing	Additional description: Throat clearing		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Tonsillar hypertrophy	Additional description: Tonsillar hypertrophy		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Psychiatric disorders			
Agitation	Additional description: Agitation		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2	
Aggression	Additional description: Aggression		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Anxiety disorder	Additional description: Anxiety disorder		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Anxiety	Additional description: Anxiety		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	0 / 170 (0.00%) 0	
Aversion	Additional description: Aversion		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Depressed mood	Additional description: Depressed mood		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	0 / 170 (0.00%) 0	
Confusional state	Additional description: Confusional state		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	

Depression subjects affected / exposed occurrences (all)	Additional description: Depression	
	4 / 168 (2.38%) 4	3 / 170 (1.76%) 3
Initial insomnia subjects affected / exposed occurrences (all)	Additional description: Initial insomnia	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	Additional description: Insomnia	
	5 / 168 (2.98%) 6	5 / 170 (2.94%) 5
Libido decreased subjects affected / exposed occurrences (all)	Additional description: Libido decreased	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Listless subjects affected / exposed occurrences (all)	Additional description: Listless	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Mood altered subjects affected / exposed occurrences (all)	Additional description: Mood altered	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Nervousness subjects affected / exposed occurrences (all)	Additional description: Nervousness	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Panic attack subjects affected / exposed occurrences (all)	Additional description: Panic attack	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Psychotic disorder subjects affected / exposed occurrences (all)	Additional description: Psychotic disorder	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Restlessness subjects affected / exposed occurrences (all)	Additional description: Restlessness	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Sleep disorder subjects affected / exposed occurrences (all)	Additional description: Sleep disorder	
	1 / 168 (0.60%) 1	10 / 170 (5.88%) 12
Investigations Alanine aminotransferase increased	Additional description: Alanine aminotransferase increased	

subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	3 / 170 (1.76%) 6	
Arthroscopy	Additional description: Arthroscopy		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Aspartate aminotransferase increased	Additional description: Aspartate aminotransferase increased		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	3 / 170 (1.76%) 4	
Biopsy prostate	Additional description: Biopsy prostate		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Blood alkaline phosphatase increased	Additional description: Blood alkaline phosphatase increased		
subjects affected / exposed occurrences (all)	3 / 168 (1.79%) 3	0 / 170 (0.00%) 0	
Blood bilirubin increased	Additional description: Blood bilirubin increased		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 6	
Blood cholesterol increased	Additional description: Blood cholesterol increased		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	0 / 170 (0.00%) 0	
Blood creatine phosphokinase increased	Additional description: Blood creatine phosphokinase increased		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Blood creatinine increased	Additional description: Blood creatinine increased		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	3 / 170 (1.76%) 3	
Blood glucose increased	Additional description: Blood glucose increased		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Blood immunoglobulin G decreased	Additional description: Blood immunoglobulin G decreased		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2	
Blood lactate dehydrogenase increased	Additional description: Blood lactate dehydrogenase increased		

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Blood potassium decreased	Additional description: Blood potassium decreased		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2	
Blood thyroid stimulating hormone increased	Additional description: Blood thyroid stimulating hormone increased		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Blood uric acid increased	Additional description: Blood uric acid increased		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2	
Cardiac murmur	Additional description: Cardiac murmur		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Blood urea increased	Additional description: Blood urea increased		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 3	
Electrocardiogram repolarisation abnormality	Additional description: Electrocardiogram repolarisation abnormality		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Electrocardiogram ST segment depression	Additional description: Electrocardiogram ST segment depression		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Gamma-glutamyltransferase increased	Additional description: Gamma-glutamyltransferase increased		
subjects affected / exposed occurrences (all)	3 / 168 (1.79%) 3	3 / 170 (1.76%) 4	
Hepatic enzyme increased	Additional description: Hepatic enzyme increased		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Heart rate irregular	Additional description: Heart rate irregular		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Immunoglobulins decreased	Additional description: Immunoglobulins decreased		

subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	0 / 170 (0.00%) 0	
Lipase increased	Additional description: Lipase increased		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Prostatic specific antigen increased	Additional description: Prostatic specific antigen increased		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Smear cervix	Additional description: Smear cervix		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Transaminases increased	Additional description: Transaminases increased		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	3 / 170 (1.76%) 4	
Urine uric acid increased	Additional description: Urine uric acid increased		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Weight increased	Additional description: Weight increased		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	3 / 170 (1.76%) 3	
Weight decreased	Additional description: Weight decreased		
subjects affected / exposed occurrences (all)	3 / 168 (1.79%) 4	4 / 170 (2.35%) 4	
Injury, poisoning and procedural complications			
Acetabulum fracture	Additional description: Acetabulum fracture		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Accident at work	Additional description: Accident at work		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Animal scratch	Additional description: Animal scratch		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Ankle fracture	Additional description: Ankle fracture		

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	3 / 170 (1.76%) 3	
Arthropod bite	Additional description: Arthropod bite		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	4 / 170 (2.35%) 7	
Arthropod sting	Additional description: Arthropod sting		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Bone contusion	Additional description: Bone contusion		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Burn oral cavity	Additional description: Burn oral cavity		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Cartilage injury	Additional description: Cartilage injury		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Concussion	Additional description: Concussion		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Contusion	Additional description: Contusion		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	8 / 170 (4.71%) 10	
Fall	Additional description: Fall		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	2 / 170 (1.18%) 2	
Foot fracture	Additional description: Foot fracture		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Fracture	Additional description: Fracture		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Hand fracture	Additional description: Hand fracture		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Ilium fracture	Additional description: Ilium fracture		

subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Joint injury	Additional description: Joint injury		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Infusion related reaction	Additional description: Infusion related reaction		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Injury corneal	Additional description: Injury corneal		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Laceration	Additional description: Laceration		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Ligament rupture	Additional description: Ligament rupture		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	4 / 170 (2.35%) 4	
Ligament sprain	Additional description: Ligament sprain		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Limb injury	Additional description: Limb injury		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Lumbar vertebral fracture	Additional description: Lumbar vertebral fracture		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Muscle rupture	Additional description: Muscle rupture		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Meniscus injury	Additional description: Meniscus injury		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	2 / 170 (1.18%) 2	
Muscle strain	Additional description: Muscle strain		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Nail avulsion	Additional description: Nail avulsion		

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Patella fracture	Additional description: Patella fracture		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Post-traumatic pain	Additional description: Post-traumatic pain		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Skin laceration	Additional description: Skin laceration		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Spinal compression fracture	Additional description: Spinal compression fracture		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Spinal fracture	Additional description: Spinal fracture		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Skin abrasion	Additional description: Skin abrasion		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Sunburn	Additional description: Sunburn		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Traumatic fracture	Additional description: Traumatic fracture		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Traumatic haematoma	Additional description: Traumatic haematoma		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 3	
Wound complication	Additional description: Wound complication		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Wound	Additional description: Wound		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Congenital, familial and genetic			

disorders		
Atrial septal defect	Additional description: Atrial septal defect	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Factor V Leiden mutation	Additional description: Factor V Leiden mutation	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Hereditary motor and sensory neuropathy	Additional description: Hereditary motor and sensory neuropathy	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Hydrocele	Additional description: Hydrocele	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Phimosis	Additional description: Phimosis	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Cardiac disorders		
Acute myocardial infarction	Additional description: Acute myocardial infarction	
subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)
occurrences (all)	2	0
Angina pectoris	Additional description: Angina pectoris	
subjects affected / exposed	2 / 168 (1.19%)	1 / 170 (0.59%)
occurrences (all)	2	1
Aortic valve incompetence	Additional description: Aortic valve incompetence	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Arrhythmia	Additional description: Arrhythmia	
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)
occurrences (all)	1	1
Arteriosclerosis coronary artery	Additional description: Arteriosclerosis coronary artery	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Atrial fibrillation	Additional description: Atrial fibrillation	
subjects affected / exposed	2 / 168 (1.19%)	16 / 170 (9.41%)
occurrences (all)	9	16
Atrioventricular block first degree	Additional description: Atrioventricular block first degree	

subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Cardiovascular disorder	Additional description: Cardiovascular disorder		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 6	
Bradycardia	Additional description: Bradycardia		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Cardiac failure	Additional description: Cardiac failure		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Cardiomegaly	Additional description: Cardiomegaly		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Coronary artery disease	Additional description: Coronary artery disease		
subjects affected / exposed occurrences (all)	3 / 168 (1.79%) 3	1 / 170 (0.59%) 1	
Coronary artery stenosis	Additional description: Coronary artery stenosis		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 2	0 / 170 (0.00%) 0	
Extrasystoles	Additional description: Extrasystoles		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2	
Hypertensive heart disease	Additional description: Hypertensive heart disease		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Left ventricular hypertrophy	Additional description: Left ventricular hypertrophy		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Mitral valve incompetence	Additional description: Mitral valve incompetence		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Palpitations	Additional description: Palpitations		
subjects affected / exposed occurrences (all)	5 / 168 (2.98%) 6	3 / 170 (1.76%) 4	
Pericardial effusion	Additional description: Pericardial effusion		

subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Sinus tachycardia	Additional description: Sinus tachycardia		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	0 / 170 (0.00%) 0	
Sinus bradycardia	Additional description: Sinus bradycardia		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Tachyarrhythmia	Additional description: Tachyarrhythmia		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Tachycardia	Additional description: Tachycardia		
subjects affected / exposed occurrences (all)	4 / 168 (2.38%) 4	5 / 170 (2.94%) 5	
Tricuspid valve incompetence	Additional description: Tricuspid valve incompetence		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Ventricular extrasystoles	Additional description: Ventricular extrasystoles		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	1 / 170 (0.59%) 1	
Nervous system disorders			
Ageusia	Additional description: Ageusia		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Balance disorder	Additional description: Balance disorder		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Basilar migraine	Additional description: Basilar migraine		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Cognitive disorder	Additional description: Cognitive disorder		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Carotid artery stenosis	Additional description: Carotid artery stenosis		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	

Carpal tunnel syndrome subjects affected / exposed occurrences (all)	Additional description: Carpal tunnel syndrome	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Cervical syndrome subjects affected / exposed occurrences (all)	Additional description: Cervical syndrome	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Cervicobrachial syndrome subjects affected / exposed occurrences (all)	Additional description: Cervicobrachial syndrome	
	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2
Convulsion subjects affected / exposed occurrences (all)	Additional description: Convulsion	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Dementia subjects affected / exposed occurrences (all)	Additional description: Dementia	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	Additional description: Dizziness	
	11 / 168 (6.55%) 13	26 / 170 (15.29%) 41
Diabetic neuropathy subjects affected / exposed occurrences (all)	Additional description: Diabetic neuropathy	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Disturbance in attention subjects affected / exposed occurrences (all)	Additional description: Disturbance in attention	
	0 / 168 (0.00%) 0	2 / 170 (1.18%) 3
Dysaesthesia subjects affected / exposed occurrences (all)	Additional description: Dysaesthesia	
	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2
Dysgeusia subjects affected / exposed occurrences (all)	Additional description: Dysgeusia	
	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2
Headache subjects affected / exposed occurrences (all)	Additional description: Headache	
	20 / 168 (11.90%) 39	30 / 170 (17.65%) 48
Hypertonia subjects affected / exposed occurrences (all)	Additional description: Hypertonia	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1

Hypoaesthesia	Additional description: Hypoaesthesia	
subjects affected / exposed	1 / 168 (0.60%)	4 / 170 (2.35%)
occurrences (all)	1	4
Hypoaesthesia oral	Additional description: Hypoaesthesia oral	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Intercostal neuralgia	Additional description: Intercostal neuralgia	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Loss of consciousness	Additional description: Loss of consciousness	
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)
occurrences (all)	0	2
Muscle spasticity	Additional description: Muscle spasticity	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Memory impairment	Additional description: Memory impairment	
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)
occurrences (all)	1	1
Migraine	Additional description: Migraine	
subjects affected / exposed	2 / 168 (1.19%)	1 / 170 (0.59%)
occurrences (all)	3	1
Neuralgia	Additional description: Neuralgia	
subjects affected / exposed	1 / 168 (0.60%)	2 / 170 (1.18%)
occurrences (all)	1	2
Neuropathy peripheral	Additional description: Neuropathy peripheral	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Paraesthesia	Additional description: Paraesthesia	
subjects affected / exposed	1 / 168 (0.60%)	8 / 170 (4.71%)
occurrences (all)	1	12
Paraparesis	Additional description: Paraparesis	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Parkinson's disease	Additional description: Parkinson's disease	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1

Parosmia	Additional description: Parosmia	
subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)
occurrences (all)	2	0
Polyneuropathy	Additional description: Polyneuropathy	
subjects affected / exposed	2 / 168 (1.19%)	6 / 170 (3.53%)
occurrences (all)	2	6
Radiculopathy	Additional description: Radiculopathy	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Sciatica	Additional description: Sciatica	
subjects affected / exposed	1 / 168 (0.60%)	2 / 170 (1.18%)
occurrences (all)	1	2
Syncope	Additional description: Syncope	
subjects affected / exposed	0 / 168 (0.00%)	3 / 170 (1.76%)
occurrences (all)	0	3
Tremor	Additional description: Tremor	
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)
occurrences (all)	1	1
Vascular encephalopathy	Additional description: Vascular encephalopathy	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Blood and lymphatic system disorders		
Anaemia	Additional description: Anaemia	
subjects affected / exposed	4 / 168 (2.38%)	4 / 170 (2.35%)
occurrences (all)	4	4
Coagulopathy	Additional description: Coagulopathy	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Eosinophilia	Additional description: Eosinophilia	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Haemorrhagic diathesis	Additional description: Haemorrhagic diathesis	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Immune thrombocytopenia	Additional description: Immune thrombocytopenia	

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Iron deficiency anaemia	Additional description: Iron deficiency anaemia		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Leukocytosis	Additional description: Leukocytosis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Lymph node pain	Additional description: Lymph node pain		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Lymphadenopathy	Additional description: Lymphadenopathy		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Neutropenia	Additional description: Neutropenia		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	2 / 170 (1.18%) 3	
Splenomegaly	Additional description: Splenomegaly		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Thrombocytopenia	Additional description: Thrombocytopenia		
subjects affected / exposed occurrences (all)	3 / 168 (1.79%) 4	5 / 170 (2.94%) 5	
Ear and labyrinth disorders			
Ear disorder	Additional description: Ear disorder		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Ear discomfort	Additional description: Ear discomfort		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Ear pain	Additional description: Ear pain		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Ear pruritus	Additional description: Ear pruritus		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	

Ear swelling subjects affected / exposed occurrences (all)	Additional description: Ear swelling	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Ear haemorrhage subjects affected / exposed occurrences (all)	Additional description: Ear haemorrhage	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Hyperacusis subjects affected / exposed occurrences (all)	Additional description: Hyperacusis	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Sudden hearing loss subjects affected / exposed occurrences (all)	Additional description: Sudden hearing loss	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Tinnitus subjects affected / exposed occurrences (all)	Additional description: Tinnitus	
	2 / 168 (1.19%) 2	1 / 170 (0.59%) 1
Vertigo subjects affected / exposed occurrences (all)	Additional description: Vertigo	
	8 / 168 (4.76%) 8	12 / 170 (7.06%) 17
Vertigo positional subjects affected / exposed occurrences (all)	Additional description: Vertigo positional	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Eye disorders		
	Additional description: Blepharitis	
Blepharitis subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
	Additional description: Blepharospasm	
Blepharospasm subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
	Additional description: Blindness	
Blindness subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
	Additional description: Cataract	
Cataract subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	6 / 170 (3.53%) 6
	Additional description: Conjunctival haemorrhage	
Conjunctival haemorrhage		

subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	1 / 170 (0.59%) 1	
Dacryostenosis acquired	Additional description: Dacryostenosis acquired		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Diplopia	Additional description: Diplopia		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Dry eye	Additional description: Dry eye		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2	
Eye haematoma	Additional description: Eye haematoma		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Eye inflammation	Additional description: Eye inflammation		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2	
Eye pruritus	Additional description: Eye pruritus		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Glaucoma	Additional description: Glaucoma		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Macular degeneration	Additional description: Macular degeneration		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Macular oedema	Additional description: Macular oedema		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Posterior capsule opacification	Additional description: Posterior capsule opacification		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Vision blurred	Additional description: Vision blurred		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	3 / 170 (1.76%) 3	
Visual acuity reduced	Additional description: Visual acuity reduced		

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2	
Visual impairment	Additional description: Visual impairment		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2	
Gastrointestinal disorders			
Abdominal pain lower	Additional description: Abdominal pain lower		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2	
Abdominal pain	Additional description: Abdominal pain		
subjects affected / exposed occurrences (all)	11 / 168 (6.55%) 12	6 / 170 (3.53%) 8	
Abdominal distension	Additional description: Abdominal distension		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	2 / 170 (1.18%) 2	
Abdominal discomfort	Additional description: Abdominal discomfort		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	2 / 170 (1.18%) 2	
Abdominal pain upper	Additional description: Abdominal pain upper		
subjects affected / exposed occurrences (all)	13 / 168 (7.74%) 14	11 / 170 (6.47%) 12	
Angular cheilitis	Additional description: Angular cheilitis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Anal inflammation	Additional description: Anal inflammation		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Anal fistula	Additional description: Anal fistula		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 2	0 / 170 (0.00%) 0	
Aphthous ulcer	Additional description: Aphthous ulcer		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 3	
Ascites	Additional description: Ascites		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	

Cheilitis	Additional description: Cheilitis	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Chronic gastritis	Additional description: Chronic gastritis	
subjects affected / exposed	2 / 168 (1.19%)	0 / 170 (0.00%)
occurrences (all)	2	0
Constipation	Additional description: Constipation	
subjects affected / exposed	6 / 168 (3.57%)	9 / 170 (5.29%)
occurrences (all)	9	9
Dental caries	Additional description: Dental caries	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Diarrhoea	Additional description: Diarrhoea	
subjects affected / exposed	31 / 168 (18.45%)	58 / 170 (34.12%)
occurrences (all)	48	101
Diarrhoea haemorrhagic	Additional description: Diarrhoea haemorrhagic	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Diverticulum	Additional description: Diverticulum	
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)
occurrences (all)	1	1
Diverticulum intestinal	Additional description: Diverticulum intestinal	
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)
occurrences (all)	1	1
Dry mouth	Additional description: Dry mouth	
subjects affected / exposed	6 / 168 (3.57%)	14 / 170 (8.24%)
occurrences (all)	7	15
Dyspepsia	Additional description: Dyspepsia	
subjects affected / exposed	6 / 168 (3.57%)	27 / 170 (15.88%)
occurrences (all)	7	66
Dysphagia	Additional description: Dysphagia	
subjects affected / exposed	0 / 168 (0.00%)	3 / 170 (1.76%)
occurrences (all)	0	3
Epigastric discomfort	Additional description: Epigastric discomfort	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1

Eructation subjects affected / exposed occurrences (all)	Additional description: Eructation	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Gastric disorder subjects affected / exposed occurrences (all)	Additional description: Gastric disorder	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Flatulence subjects affected / exposed occurrences (all)	Additional description: Flatulence	
	3 / 168 (1.79%) 3	4 / 170 (2.35%) 5
Frequent bowel movements subjects affected / exposed occurrences (all)	Additional description: Frequent bowel movements	
	2 / 168 (1.19%) 2	0 / 170 (0.00%) 0
Glossodynia subjects affected / exposed occurrences (all)	Additional description: Glossodynia	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Gastritis subjects affected / exposed occurrences (all)	Additional description: Gastritis	
	0 / 168 (0.00%) 0	7 / 170 (4.12%) 7
Gastrointestinal disorder subjects affected / exposed occurrences (all)	Additional description: Gastrointestinal disorder	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Gastrointestinal pain subjects affected / exposed occurrences (all)	Additional description: Gastrointestinal pain	
	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2
Gastrooesophageal reflux disease subjects affected / exposed occurrences (all)	Additional description: Gastrooesophageal reflux disease	
	2 / 168 (1.19%) 2	7 / 170 (4.12%) 7
Gingival bleeding subjects affected / exposed occurrences (all)	Additional description: Gingival bleeding	
	1 / 168 (0.60%) 1	2 / 170 (1.18%) 3
Gingival disorder subjects affected / exposed occurrences (all)	Additional description: Gingival disorder	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Gingival swelling subjects affected / exposed occurrences (all)	Additional description: Gingival swelling	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1

Gingivitis ulcerative subjects affected / exposed occurrences (all)	Additional description: Gingivitis ulcerative	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Glossitis subjects affected / exposed occurrences (all)	Additional description: Glossitis	
	0 / 168 (0.00%) 0	3 / 170 (1.76%) 7
Gastric ulcer subjects affected / exposed occurrences (all)	Additional description: Gastric ulcer	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Haematochezia subjects affected / exposed occurrences (all)	Additional description: Haematochezia	
	1 / 168 (0.60%) 1	3 / 170 (1.76%) 3
Haemorrhoids subjects affected / exposed occurrences (all)	Additional description: Haemorrhoids	
	4 / 168 (2.38%) 5	2 / 170 (1.18%) 2
Haemorrhoids thrombosed subjects affected / exposed occurrences (all)	Additional description: Haemorrhoids thrombosed	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Hiatus hernia subjects affected / exposed occurrences (all)	Additional description: Hiatus hernia	
	3 / 168 (1.79%) 3	2 / 170 (1.18%) 2
Intestinal polyp subjects affected / exposed occurrences (all)	Additional description: Intestinal polyp	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Large intestine polyp subjects affected / exposed occurrences (all)	Additional description: Large intestine polyp	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Lip blister subjects affected / exposed occurrences (all)	Additional description: Lip blister	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2
Loose tooth subjects affected / exposed occurrences (all)	Additional description: Loose tooth	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Mouth swelling subjects affected / exposed occurrences (all)	Additional description: Mouth swelling	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1

Mouth ulceration subjects affected / exposed occurrences (all)	Additional description: Mouth ulceration	
	0 / 168 (0.00%) 0	2 / 170 (1.18%) 4
Melaena subjects affected / exposed occurrences (all)	Additional description: Melaena	
	2 / 168 (1.19%) 2	1 / 170 (0.59%) 1
Mouth haemorrhage subjects affected / exposed occurrences (all)	Additional description: Mouth haemorrhage	
	0 / 168 (0.00%) 0	2 / 170 (1.18%) 3
Nausea subjects affected / exposed occurrences (all)	Additional description: Nausea	
	20 / 168 (11.90%) 30	32 / 170 (18.82%) 57
Noninfective gingivitis subjects affected / exposed occurrences (all)	Additional description: Noninfective gingivitis	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Obstruction gastric subjects affected / exposed occurrences (all)	Additional description: Obstruction gastric	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2
Oesophageal pain subjects affected / exposed occurrences (all)	Additional description: Oesophageal pain	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Oesophagitis subjects affected / exposed occurrences (all)	Additional description: Oesophagitis	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Oral disorder subjects affected / exposed occurrences (all)	Additional description: Oral disorder	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Oral pain subjects affected / exposed occurrences (all)	Additional description: Oral pain	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Pancreatic cyst subjects affected / exposed occurrences (all)	Additional description: Pancreatic cyst	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Paraesthesia oral subjects affected / exposed occurrences (all)	Additional description: Paraesthesia oral	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1

Proctitis	Additional description: Proctitis	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	2
Rectal prolapse	Additional description: Rectal prolapse	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Salivary gland enlargement	Additional description: Salivary gland enlargement	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Stomatitis	Additional description: Stomatitis	
subjects affected / exposed	2 / 168 (1.19%)	13 / 170 (7.65%)
occurrences (all)	2	20
Subileus	Additional description: Subileus	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Tongue blistering	Additional description: Tongue blistering	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Tongue ulceration	Additional description: Tongue ulceration	
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)
occurrences (all)	1	1
Toothache	Additional description: Toothache	
subjects affected / exposed	3 / 168 (1.79%)	3 / 170 (1.76%)
occurrences (all)	3	4
Umbilical hernia	Additional description: Umbilical hernia	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Vomiting	Additional description: Vomiting	
subjects affected / exposed	7 / 168 (4.17%)	13 / 170 (7.65%)
occurrences (all)	9	16
Hepatobiliary disorders		
Cholecystitis acute	Additional description: Cholecystitis acute	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Cholelithiasis	Additional description: Cholelithiasis	

subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Hepatic cyst	Additional description: Hepatic cyst		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Hepatic steatosis	Additional description: Hepatic steatosis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Hyperbilirubinaemia	Additional description: Hyperbilirubinaemia		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Skin and subcutaneous tissue disorders			
Actinic keratosis	Additional description: Actinic keratosis		
subjects affected / exposed occurrences (all)	4 / 168 (2.38%) 4	2 / 170 (1.18%) 4	
Alopecia areata	Additional description: Alopecia areata		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Alopecia	Additional description: Alopecia		
subjects affected / exposed occurrences (all)	4 / 168 (2.38%) 4	5 / 170 (2.94%) 5	
Asteatosis	Additional description: Asteatosis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Blood blister	Additional description: Blood blister		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Butterfly rash	Additional description: Butterfly rash		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Dandruff	Additional description: Dandruff		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Dermatitis	Additional description: Dermatitis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 3	

Dermatitis acneiform subjects affected / exposed occurrences (all)	Additional description: Dermatitis acneiform	
	0 / 168 (0.00%) 0	3 / 170 (1.76%) 5
Dermatitis allergic subjects affected / exposed occurrences (all)	Additional description: Dermatitis allergic	
	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2
Dermatitis atopic subjects affected / exposed occurrences (all)	Additional description: Dermatitis atopic	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Dermatitis bullous subjects affected / exposed occurrences (all)	Additional description: Dermatitis bullous	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Dermatosis subjects affected / exposed occurrences (all)	Additional description: Dermatitis	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Dermal cyst subjects affected / exposed occurrences (all)	Additional description: Dermal cyst	
	1 / 168 (0.60%) 1	3 / 170 (1.76%) 3
Ecchymosis subjects affected / exposed occurrences (all)	Additional description: Ecchymosis	
	1 / 168 (0.60%) 1	2 / 170 (1.18%) 3
Eczema subjects affected / exposed occurrences (all)	Additional description: Eczema	
	1 / 168 (0.60%) 1	7 / 170 (4.12%) 9
Drug eruption subjects affected / exposed occurrences (all)	Additional description: Drug eruption	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Dry skin subjects affected / exposed occurrences (all)	Additional description: Dry skin	
	5 / 168 (2.98%) 5	16 / 170 (9.41%) 19
Erythema subjects affected / exposed occurrences (all)	Additional description: Erythema	
	1 / 168 (0.60%) 1	3 / 170 (1.76%) 3
Haemorrhage subcutaneous subjects affected / exposed occurrences (all)	Additional description: Haemorrhage subcutaneous	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1

Hair colour changes subjects affected / exposed occurrences (all)	Additional description: Hair colour changes	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Hair growth abnormal subjects affected / exposed occurrences (all)	Additional description: Hair growth abnormal	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Hyperhidrosis subjects affected / exposed occurrences (all)	Additional description: Hyperhidrosis	
	7 / 168 (4.17%) 10	4 / 170 (2.35%) 4
Hyperkeratosis subjects affected / exposed occurrences (all)	Additional description: Hyperkeratosis	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Ingrowing nail subjects affected / exposed occurrences (all)	Additional description: Ingrowing nail	
	0 / 168 (0.00%) 0	5 / 170 (2.94%) 5
Nail atrophy subjects affected / exposed occurrences (all)	Additional description: Nail atrophy	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Nail bed inflammation subjects affected / exposed occurrences (all)	Additional description: Nail bed inflammation	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Nail disorder subjects affected / exposed occurrences (all)	Additional description: Nail disorder	
	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2
Nail dystrophy subjects affected / exposed occurrences (all)	Additional description: Nail dystrophy	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Nail ridging subjects affected / exposed occurrences (all)	Additional description: Nail ridging	
	0 / 168 (0.00%) 0	4 / 170 (2.35%) 4
Night sweats subjects affected / exposed occurrences (all)	Additional description: Night sweats	
	9 / 168 (5.36%) 14	5 / 170 (2.94%) 7
Onychoclasia subjects affected / exposed occurrences (all)	Additional description: Onychoclasia	
	3 / 168 (1.79%) 3	19 / 170 (11.18%) 19

Onycholysis	Additional description: Onycholysis	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Pain of skin	Additional description: Pain of skin	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Petechiae	Additional description: Petechiae	
subjects affected / exposed	0 / 168 (0.00%)	7 / 170 (4.12%)
occurrences (all)	0	9
Photosensitivity reaction	Additional description: Photosensitivity reaction	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Polymorphic light eruption	Additional description: Polymorphic light eruption	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Pruritus	Additional description: Pruritus	
subjects affected / exposed	6 / 168 (3.57%)	13 / 170 (7.65%)
occurrences (all)	7	15
Psoriasis	Additional description: Psoriasis	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Purpura	Additional description: Purpura	
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)
occurrences (all)	0	2
Rash	Additional description: Rash	
subjects affected / exposed	10 / 168 (5.95%)	33 / 170 (19.41%)
occurrences (all)	15	44
Rash erythematous	Additional description: Rash erythematous	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Rash maculo-papular	Additional description: Rash maculo-papular	
subjects affected / exposed	1 / 168 (0.60%)	2 / 170 (1.18%)
occurrences (all)	1	9
Rash papular	Additional description: Rash papular	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0

Scalp disorder	Additional description: Scalp disorder	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Seborrhoeic dermatitis	Additional description: Seborrhoeic dermatitis	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Skin discolouration	Additional description: Skin discolouration	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Skin disorder	Additional description: Skin disorder	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Skin erosion	Additional description: Skin erosion	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Skin fissures	Additional description: Skin fissures	
subjects affected / exposed	0 / 168 (0.00%)	8 / 170 (4.71%)
occurrences (all)	0	10
Skin haemorrhage	Additional description: Skin haemorrhage	
subjects affected / exposed	1 / 168 (0.60%)	2 / 170 (1.18%)
occurrences (all)	1	2
Skin hyperpigmentation	Additional description: Skin hyperpigmentation	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Skin induration	Additional description: Skin induration	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Skin irritation	Additional description: Skin irritation	
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)
occurrences (all)	0	2
Skin lesion	Additional description: Skin lesion	
subjects affected / exposed	0 / 168 (0.00%)	3 / 170 (1.76%)
occurrences (all)	0	3
Skin sensitisation	Additional description: Skin sensitisation	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1

Skin ulcer subjects affected / exposed occurrences (all)	Additional description: Skin ulcer	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Swelling face subjects affected / exposed occurrences (all)	Additional description: Swelling face	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	Additional description: Urticaria	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Renal and urinary disorders		
Chromaturia subjects affected / exposed occurrences (all)	Additional description: Chromaturia	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Cystitis noninfective subjects affected / exposed occurrences (all)	Additional description: Cystitis noninfective	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Dysuria subjects affected / exposed occurrences (all)	Additional description: Dysuria	
	2 / 168 (1.19%) 2	2 / 170 (1.18%) 3
Haematuria subjects affected / exposed occurrences (all)	Additional description: Haematuria	
	3 / 168 (1.79%) 4	6 / 170 (3.53%) 9
Incontinence subjects affected / exposed occurrences (all)	Additional description: Incontinence	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Micturition urgency subjects affected / exposed occurrences (all)	Additional description: Micturition urgency	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Nocturia subjects affected / exposed occurrences (all)	Additional description: Nocturia	
	3 / 168 (1.79%) 3	1 / 170 (0.59%) 1
Pollakiuria subjects affected / exposed occurrences (all)	Additional description: Pollakiuria	
	6 / 168 (3.57%) 6	0 / 170 (0.00%) 0
Renal cyst	Additional description: Renal cyst	

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Renal failure	Additional description: Renal failure		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	3 / 170 (1.76%) 3	
Renal pain	Additional description: Renal pain		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Urinary incontinence	Additional description: Urinary incontinence		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Endocrine disorders			
Goitre	Additional description: Goitre		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Hashimoto's disease	Additional description: Hashimoto's disease		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Hyperparathyroidism	Additional description: Hyperparathyroidism		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Hyperparathyroidism secondary	Additional description: Hyperparathyroidism secondary		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Hypogonadism	Additional description: Hypogonadism		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Hypothyroidism	Additional description: Hypothyroidism		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Thyroid calcification	Additional description: Thyroid calcification		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Thyroid mass	Additional description: Thyroid mass		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	

Type 2 diabetes mellitus subjects affected / exposed occurrences (all)	Additional description: Type 2 diabetes mellitus	
	1 / 168 (0.60%)	0 / 170 (0.00%)
	1	0
Musculoskeletal and connective tissue disorders		
Arthralgia subjects affected / exposed occurrences (all)	Additional description: Arthralgia	
	15 / 168 (8.93%)	30 / 170 (17.65%)
	18	37
Arthritis subjects affected / exposed occurrences (all)	Additional description: Arthritis	
	1 / 168 (0.60%)	2 / 170 (1.18%)
	1	2
Arthritis reactive subjects affected / exposed occurrences (all)	Additional description: Arthritis reactive	
	1 / 168 (0.60%)	0 / 170 (0.00%)
	1	0
Arthropathy subjects affected / exposed occurrences (all)	Additional description: Arthropathy	
	1 / 168 (0.60%)	0 / 170 (0.00%)
	1	0
Back pain subjects affected / exposed occurrences (all)	Additional description: Back pain	
	20 / 168 (11.90%)	20 / 170 (11.76%)
	24	24
Barrel chest subjects affected / exposed occurrences (all)	Additional description: Barrel chest	
	1 / 168 (0.60%)	0 / 170 (0.00%)
	1	0
Bone pain subjects affected / exposed occurrences (all)	Additional description: Bone pain	
	2 / 168 (1.19%)	2 / 170 (1.18%)
	2	2
Bursitis subjects affected / exposed occurrences (all)	Additional description: Bursitis	
	2 / 168 (1.19%)	2 / 170 (1.18%)
	2	2
Collagen disorder subjects affected / exposed occurrences (all)	Additional description: Collagen disorder	
	0 / 168 (0.00%)	1 / 170 (0.59%)
	0	1
Exostosis subjects affected / exposed occurrences (all)	Additional description: Exostosis	
	1 / 168 (0.60%)	2 / 170 (1.18%)
	1	2
Flank pain	Additional description: Flank pain	

subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	2 / 170 (1.18%) 2	
Foot deformity	Additional description: Foot deformity		
subjects affected / exposed occurrences (all)	3 / 168 (1.79%) 3	1 / 170 (0.59%) 1	
Groin pain	Additional description: Groin pain		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Hypercreatinaemia	Additional description: Hypercreatinaemia		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	1 / 170 (0.59%) 1	
Joint effusion	Additional description: Joint effusion		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Joint swelling	Additional description: Joint swelling		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Intervertebral disc disorder	Additional description: Intervertebral disc disorder		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Intervertebral disc protrusion	Additional description: Intervertebral disc protrusion		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	3 / 170 (1.76%) 3	
Jaw cyst	Additional description: Jaw cyst		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Limb discomfort	Additional description: Limb discomfort		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Muscle atrophy	Additional description: Muscle atrophy		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Muscle spasms	Additional description: Muscle spasms		
subjects affected / exposed occurrences (all)	6 / 168 (3.57%) 9	25 / 170 (14.71%) 52	
Muscle twitching	Additional description: Muscle twitching		

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Muscular weakness	Additional description: Muscular weakness		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 3	3 / 170 (1.76%) 3	
Musculoskeletal chest pain	Additional description: Musculoskeletal chest pain		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Musculoskeletal disorder	Additional description: Musculoskeletal disorder		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Musculoskeletal pain	Additional description: Musculoskeletal pain		
subjects affected / exposed occurrences (all)	5 / 168 (2.98%) 6	4 / 170 (2.35%) 5	
Musculoskeletal stiffness	Additional description: Musculoskeletal stiffness		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2	
Myalgia	Additional description: Myalgia		
subjects affected / exposed occurrences (all)	8 / 168 (4.76%) 9	12 / 170 (7.06%) 12	
Myositis	Additional description: Myositis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Neck pain	Additional description: Neck pain		
subjects affected / exposed occurrences (all)	4 / 168 (2.38%) 4	2 / 170 (1.18%) 2	
Muscle tightness	Additional description: Muscle tightness		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	3 / 170 (1.76%) 3	
Osteoporosis	Additional description: Osteoporosis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Pain in extremity	Additional description: Pain in extremity		
subjects affected / exposed occurrences (all)	15 / 168 (8.93%) 17	15 / 170 (8.82%) 21	
Pain in jaw	Additional description: Pain in jaw		

subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Osteoarthritis	Additional description: Osteoarthritis		
subjects affected / exposed occurrences (all)	11 / 168 (6.55%) 11	3 / 170 (1.76%) 4	
Periarthritis	Additional description: Periarthritis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Periostitis	Additional description: Periostitis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Plantar fasciitis	Additional description: Plantar fasciitis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Plica syndrome	Additional description: Plica syndrome		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Rheumatic disorder	Additional description: Rheumatic disorder		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Spinal osteoarthritis	Additional description: Spinal osteoarthritis		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Spinal pain	Additional description: Spinal pain		
subjects affected / exposed occurrences (all)	2 / 168 (1.19%) 2	0 / 170 (0.00%) 0	
Spinal stenosis	Additional description: Spinal stenosis		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Synovial cyst	Additional description: Synovial cyst		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Tendon discomfort	Additional description: Tendon discomfort		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Tendonitis	Additional description: Tendonitis		

subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Tenosynovitis	Additional description: Tenosynovitis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Torticollis	Additional description: Torticollis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Infections and infestations			
Acne pustular	Additional description: Acne pustular		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Abscess limb	Additional description: Abscess limb		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 3	
Abscess	Additional description: Abscess		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Angular cheilitis	Additional description: Angular cheilitis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2	
Alveolar osteitis	Additional description: Alveolar osteitis		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Bacterial diarrhoea	Additional description: Bacterial diarrhoea		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Arthritis infective	Additional description: Arthritis infective		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0	
Atypical pneumonia	Additional description: Atypical pneumonia		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Bacterial rhinitis	Additional description: Bacterial rhinitis		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	

Bacterial vaginosis subjects affected / exposed occurrences (all)	Additional description: Bacterial vaginosis	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Bacterial food poisoning subjects affected / exposed occurrences (all)	Additional description: Bacterial food poisoning	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Bacterial infection subjects affected / exposed occurrences (all)	Additional description: Bacterial infection	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Bacterial pyelonephritis subjects affected / exposed occurrences (all)	Additional description: Bacterial pyelonephritis	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Bronchitis subjects affected / exposed occurrences (all)	Additional description: Bronchitis	
	19 / 168 (11.31%) 21	26 / 170 (15.29%) 30
Bronchitis bacterial subjects affected / exposed occurrences (all)	Additional description: Bronchitis bacterial	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Bronchitis viral subjects affected / exposed occurrences (all)	Additional description: Bronchitis viral	
	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2
Bursitis infective subjects affected / exposed occurrences (all)	Additional description: Bursitis infective	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Campylobacter infection subjects affected / exposed occurrences (all)	Additional description: Campylobacter infection	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Candida infection subjects affected / exposed occurrences (all)	Additional description: Candida infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2
Chronic tonsillitis subjects affected / exposed occurrences (all)	Additional description: Chronic tonsillitis	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Chronic sinusitis subjects affected / exposed occurrences (all)	Additional description: Chronic sinusitis	
	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2

Cellulitis	Additional description: Cellulitis	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Conjunctivitis	Additional description: Conjunctivitis	
subjects affected / exposed	3 / 168 (1.79%)	6 / 170 (3.53%)
occurrences (all)	3	9
COVID-19	Additional description: COVID-19	
subjects affected / exposed	7 / 168 (4.17%)	7 / 170 (4.12%)
occurrences (all)	7	7
Cystitis	Additional description: Cystitis	
subjects affected / exposed	12 / 168 (7.14%)	10 / 170 (5.88%)
occurrences (all)	20	21
Cystitis bacterial	Additional description: Cystitis bacterial	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Dermatitis infected	Additional description: Dermatitis infected	
subjects affected / exposed	3 / 168 (1.79%)	0 / 170 (0.00%)
occurrences (all)	3	0
Diarrhoea infectious	Additional description: Diarrhoea infectious	
subjects affected / exposed	2 / 168 (1.19%)	3 / 170 (1.76%)
occurrences (all)	2	3
Diverticulitis	Additional description: Diverticulitis	
subjects affected / exposed	2 / 168 (1.19%)	1 / 170 (0.59%)
occurrences (all)	4	1
Ear infection	Additional description: Ear infection	
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)
occurrences (all)	1	1
Epididymitis	Additional description: Epididymitis	
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)
occurrences (all)	0	6
Erysipelas	Additional description: Erysipelas	
subjects affected / exposed	1 / 168 (0.60%)	2 / 170 (1.18%)
occurrences (all)	1	2
Eye infection	Additional description: Eye infection	
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)
occurrences (all)	0	2

Eyelid infection subjects affected / exposed occurrences (all)	Additional description: Eyelid infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Enterococcal infection subjects affected / exposed occurrences (all)	Additional description: Enterococcal infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Febrile infection subjects affected / exposed occurrences (all)	Additional description: Febrile infection	
	3 / 168 (1.79%) 3	1 / 170 (0.59%) 1
Folliculitis subjects affected / exposed occurrences (all)	Additional description: Folliculitis	
	2 / 168 (1.19%) 2	3 / 170 (1.76%) 3
Fungal infection subjects affected / exposed occurrences (all)	Additional description: Fungal infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Fungal pharyngitis subjects affected / exposed occurrences (all)	Additional description: Fungal pharyngitis	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Fungal skin infection subjects affected / exposed occurrences (all)	Additional description: Fungal skin infection	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Gastric infection subjects affected / exposed occurrences (all)	Additional description: Gastric infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Gastroenteritis subjects affected / exposed occurrences (all)	Additional description: Gastroenteritis	
	5 / 168 (2.98%) 6	5 / 170 (2.94%) 7
Gastroenteritis norovirus subjects affected / exposed occurrences (all)	Additional description: Gastroenteritis norovirus	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Gastroenteritis viral subjects affected / exposed occurrences (all)	Additional description: Gastroenteritis viral	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Gastrointestinal candidiasis subjects affected / exposed occurrences (all)	Additional description: Gastrointestinal candidiasis	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1

Gastrointestinal infection subjects affected / exposed occurrences (all)	Additional description: Gastrointestinal infection	
	13 / 168 (7.74%) 14	15 / 170 (8.82%) 26
Genital herpes subjects affected / exposed occurrences (all)	Additional description: Genital herpes	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Genital herpes zoster subjects affected / exposed occurrences (all)	Additional description: Genital herpes zoster	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Gingivitis subjects affected / exposed occurrences (all)	Additional description: Gingivitis	
	2 / 168 (1.19%) 2	2 / 170 (1.18%) 2
Haemophilus infection subjects affected / exposed occurrences (all)	Additional description: Haemophilus infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Helicobacter gastritis subjects affected / exposed occurrences (all)	Additional description: Helicobacter gastritis	
	2 / 168 (1.19%) 2	2 / 170 (1.18%) 2
Hepatitis E subjects affected / exposed occurrences (all)	Additional description: Hepatitis E	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Herpes simplex subjects affected / exposed occurrences (all)	Additional description: Herpes simplex	
	2 / 168 (1.19%) 3	0 / 170 (0.00%) 0
Herpes virus infection subjects affected / exposed occurrences (all)	Additional description: Herpes virus infection	
	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2
Herpes zoster subjects affected / exposed occurrences (all)	Additional description: Herpes zoster	
	10 / 168 (5.95%) 13	5 / 170 (2.94%) 5
Hepatitis viral subjects affected / exposed occurrences (all)	Additional description: Hepatitis viral	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Impetigo subjects affected / exposed occurrences (all)	Additional description: Impetigo	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1

Infected bite subjects affected / exposed occurrences (all)	Additional description: Infected bite	
	3 / 168 (1.79%) 3	0 / 170 (0.00%) 0
Infected bites subjects affected / exposed occurrences (all)	Additional description: Infected bites	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Infected cyst subjects affected / exposed occurrences (all)	Additional description: Infected cyst	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Infection subjects affected / exposed occurrences (all)	Additional description: Infection	
	12 / 168 (7.14%) 13	9 / 170 (5.29%) 14
Influenza subjects affected / exposed occurrences (all)	Additional description: Influenza	
	8 / 168 (4.76%) 13	12 / 170 (7.06%) 22
Injection site abscess subjects affected / exposed occurrences (all)	Additional description: Injection site abscess	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Laryngitis subjects affected / exposed occurrences (all)	Additional description: Laryngitis	
	0 / 168 (0.00%) 0	4 / 170 (2.35%) 4
Lip infection subjects affected / exposed occurrences (all)	Additional description: Lip infection	
	0 / 168 (0.00%) 0	2 / 170 (1.18%) 4
Localised infection subjects affected / exposed occurrences (all)	Additional description: Localised infection	
	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2
Lower respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Lower respiratory tract infection	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Lyme disease subjects affected / exposed occurrences (all)	Additional description: Lyme disease	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Mucosal infection subjects affected / exposed occurrences (all)	Additional description: Mucosal infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 2

Nail bed infection subjects affected / exposed occurrences (all)	Additional description: Nail bed infection	
	1 / 168 (0.60%) 1	2 / 170 (1.18%) 2
Nail infection subjects affected / exposed occurrences (all)	Additional description: Nail infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Nasal herpes subjects affected / exposed occurrences (all)	Additional description: Nasal herpes	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	Additional description: Nasopharyngitis	
	72 / 168 (42.86%) 126	51 / 170 (30.00%) 108
Neutropenic infection subjects affected / exposed occurrences (all)	Additional description: Neutropenic infection	
	2 / 168 (1.19%) 2	0 / 170 (0.00%) 0
Nosocomial infection subjects affected / exposed occurrences (all)	Additional description: Nosocomial infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Onychomycosis subjects affected / exposed occurrences (all)	Additional description: Onychomycosis	
	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1
Oral fungal infection subjects affected / exposed occurrences (all)	Additional description: Oral fungal infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Oral herpes subjects affected / exposed occurrences (all)	Additional description: Oral herpes	
	12 / 168 (7.14%) 18	2 / 170 (1.18%) 6
Oral infection subjects affected / exposed occurrences (all)	Additional description: Oral infection	
	0 / 168 (0.00%) 0	3 / 170 (1.76%) 3
Oral viral infection subjects affected / exposed occurrences (all)	Additional description: Oral viral infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Orchitis subjects affected / exposed occurrences (all)	Additional description: Orchitis	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1

Otitis externa	Additional description: Otitis externa	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Paronychia	Additional description: Paronychia	
subjects affected / exposed	1 / 168 (0.60%)	10 / 170 (5.88%)
occurrences (all)	3	12
Parotitis	Additional description: Parotitis	
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)
occurrences (all)	3	1
Penile infection	Additional description: Penile infection	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Periodontitis	Additional description: Periodontitis	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Pharyngitis	Additional description: Pharyngitis	
subjects affected / exposed	4 / 168 (2.38%)	4 / 170 (2.35%)
occurrences (all)	4	4
Phlebitis infective	Additional description: Phlebitis infective	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Pneumonia	Additional description: Pneumonia	
subjects affected / exposed	7 / 168 (4.17%)	10 / 170 (5.88%)
occurrences (all)	9	15
Postoperative wound infection	Additional description: Postoperative wound infection	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Pseudomonas infection	Additional description: Pseudomonas infection	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Purulence	Additional description: Purulence	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Pyelonephritis	Additional description: Pyelonephritis	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1

Pyoderma	Additional description: Pyoderma	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Rash pustular	Additional description: Rash pustular	
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)
occurrences (all)	0	3
Respiratory tract infection	Additional description: Respiratory tract infection	
subjects affected / exposed	8 / 168 (4.76%)	13 / 170 (7.65%)
occurrences (all)	9	23
Retinitis	Additional description: Retinitis	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Rhinitis	Additional description: Rhinitis	
subjects affected / exposed	3 / 168 (1.79%)	10 / 170 (5.88%)
occurrences (all)	5	10
Root canal infection	Additional description: Root canal infection	
subjects affected / exposed	1 / 168 (0.60%)	2 / 170 (1.18%)
occurrences (all)	1	2
Scarlet fever	Additional description: Scarlet fever	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Scrotal infection	Additional description: Scrotal infection	
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)
occurrences (all)	0	5
Seminal vesicular infection	Additional description: Seminal vesicular infection	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Sialoadenitis	Additional description: Sialoadenitis	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Sinobronchitis	Additional description: Sinobronchitis	
subjects affected / exposed	1 / 168 (0.60%)	0 / 170 (0.00%)
occurrences (all)	1	0
Sinusitis	Additional description: Sinusitis	
subjects affected / exposed	8 / 168 (4.76%)	9 / 170 (5.29%)
occurrences (all)	11	15

Sinusitis bacterial subjects affected / exposed occurrences (all)	Additional description: Sinusitis bacterial	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Skin infection subjects affected / exposed occurrences (all)	Additional description: Skin infection	
	1 / 168 (0.60%) 2	4 / 170 (2.35%) 5
Subcutaneous abscess subjects affected / exposed occurrences (all)	Additional description: Subcutaneous abscess	
	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2
Tinea infection subjects affected / exposed occurrences (all)	Additional description: Tinea infection	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Tinea versicolour subjects affected / exposed occurrences (all)	Additional description: Tinea versicolour	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	Additional description: Upper respiratory tract infection	
	17 / 168 (10.12%) 20	19 / 170 (11.18%) 30
Tongue fungal infection subjects affected / exposed occurrences (all)	Additional description: Tongue fungal infection	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0
Tonsillitis subjects affected / exposed occurrences (all)	Additional description: Tonsillitis	
	3 / 168 (1.79%) 3	3 / 170 (1.76%) 5
Tooth abscess subjects affected / exposed occurrences (all)	Additional description: Tooth abscess	
	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2
Tooth infection subjects affected / exposed occurrences (all)	Additional description: Tooth infection	
	4 / 168 (2.38%) 4	3 / 170 (1.76%) 3
Tracheitis subjects affected / exposed occurrences (all)	Additional description: Tracheitis	
	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1
Trichomoniasis subjects affected / exposed occurrences (all)	Additional description: Trichomoniasis	
	1 / 168 (0.60%) 1	0 / 170 (0.00%) 0

Tinea pedis	Additional description: Tinea pedis	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Urinary tract infection	Additional description: Urinary tract infection	
subjects affected / exposed	12 / 168 (7.14%)	20 / 170 (11.76%)
occurrences (all)	14	41
Vulvovaginal mycotic infection	Additional description: Vulvovaginal mycotic infection	
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)
occurrences (all)	1	1
Viral diarrhoea	Additional description: Viral diarrhoea	
subjects affected / exposed	1 / 168 (0.60%)	1 / 170 (0.59%)
occurrences (all)	1	1
Viral infection	Additional description: Viral infection	
subjects affected / exposed	5 / 168 (2.98%)	3 / 170 (1.76%)
occurrences (all)	5	3
Viral upper respiratory tract infection	Additional description: Viral upper respiratory tract infection	
subjects affected / exposed	2 / 168 (1.19%)	1 / 170 (0.59%)
occurrences (all)	2	1
Wound infection bacterial	Additional description: Wound infection bacterial	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Wound infection	Additional description: Wound infection	
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)
occurrences (all)	0	2
Wound infection pseudomonas	Additional description: Wound infection pseudomonas	
subjects affected / exposed	0 / 168 (0.00%)	1 / 170 (0.59%)
occurrences (all)	0	1
Metabolism and nutrition disorders		
Decreased appetite	Additional description: Decreased appetite	
subjects affected / exposed	3 / 168 (1.79%)	3 / 170 (1.76%)
occurrences (all)	5	3
Diabetes mellitus	Additional description: Diabetes mellitus	
subjects affected / exposed	0 / 168 (0.00%)	2 / 170 (1.18%)
occurrences (all)	0	2
Diabetic metabolic decompensation	Additional description: Diabetic metabolic decompensation	

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Folate deficiency	Additional description: Folate deficiency		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	3 / 170 (1.76%) 3	
Gout	Additional description: Gout		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 2	6 / 170 (3.53%) 6	
Hypercholesterolaemia	Additional description: Hypercholesterolaemia		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 3	
Hypercreatininaemia	Additional description: Hypercreatininaemia		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Hyperglycaemia	Additional description: Hyperglycaemia		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Hyperkalaemia	Additional description: Hyperkalaemia		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Hyperlipasaemia	Additional description: Hyperlipasaemia		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	1 / 170 (0.59%) 1	
Hyperuricaemia	Additional description: Hyperuricaemia		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	3 / 170 (1.76%) 3	
Hypokalaemia	Additional description: Hypokalaemia		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Iron deficiency	Additional description: Iron deficiency		
subjects affected / exposed occurrences (all)	1 / 168 (0.60%) 1	4 / 170 (2.35%) 4	
Protein deficiency	Additional description: Protein deficiency		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Type 2 diabetes mellitus	Additional description: Type 2 diabetes mellitus		

subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	2 / 170 (1.18%) 2	
Vitamin B12 deficiency	Additional description: Vitamin B12 deficiency		
subjects affected / exposed occurrences (all)	0 / 168 (0.00%) 0	1 / 170 (0.59%) 1	
Vitamin D deficiency	Additional description: Vitamin D deficiency		
subjects affected / exposed occurrences (all)	3 / 168 (1.79%) 3	4 / 170 (2.35%) 4	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
15 October 2014	New Information on Ibrutinib and update of protocol and PIC following IB V8.0
04 February 2015	Adaption of sample size calculation with respect to current recruitment rate
15 July 2015	Changes in the protocol, following DSMB recommendation to prohibit concomitant medication with Xa-Inhibitors, alternatively to allow heparines only.
13 January 2016	New Information on Ibrutinib and update of protocol and PIC following IB V9.0;Adaption of statistical assumption to allow confirmatory analyses of overall survival
08 July 2016	New safety information on interstitial lung disease, amendment of PIC accordingly
28 March 2017	New Information on Ibrutinib and update of protocol and PIC following IB V10.0
26 June 2017	New Information on Ibrutinib and update of protocol and PIC following SmPC Februar 2017; administrative changes
09 April 2018	New Information on Ibrutinib and update of protocol and PIC following SmPC August 2017; Adaption of analysis time points and details of statistical analyses

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/34758069>